Co-delivery of GOLPH3 siRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma

Ye, Chengkun; Pan, Bomin; Xu, Haoyue; Zhao, Zongren; Shen, Jia-Wei; Lü, Jun; Yu, Rutong; Liu, Hongmei

doi:10.1007/s00109-019-01843-4

Cited by 32 publications

(32 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The action of gefitinib was also investigated by Wang and collaborators, who found that both immortalized and primary glioma cells with higher GOLPH3 levels also display a higher sensitivity to gefitinib [75]. These data partly contrast with the findings of Ye and collaborators [74], described above, on the GOLPH3 levels that are coupled with the gefitinib-based therapeutic strategy. Finally, Peng and co-workers [76] demonstrated that GOLPH3 is also a direct target of miR-299-5p in GBM cell lines (T98G and A172); moreover, miR-299-5p knockdown makes GBM cells sensitive to temozolomide (TMZ) both in vitro and in vivo by impairing cell proliferation and invasion and promoting apoptosis through the inhibition of the ERK signaling pathway.…”

Section: Golph3 Deregulation and Brain Tumorsmentioning

confidence: 94%

“…Yuan and collaborators [73] targeted GOLPH3 through siRNA loaded on cationic liposomes, obtaining the inhibition of glioma growth in vivo, in a nude mouse model. A similar nanoparticle-mediated approach was used by Ye and co-workers, who co-delivered GOLPH3 siRNA and gefitinib (Ge, an anti-EGFR drug) in vitro (U87 and T98G glioma cell lines) and in vivo (BALB/c nude mice), obtaining growth inhibition and apoptosis induction [74]. The action of gefitinib was also investigated by Wang and collaborators, who found that both immortalized and primary glioma cells with higher GOLPH3 levels also display a higher sensitivity to gefitinib [75].…”

Section: Golph3 Deregulation and Brain Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

Oncogenic Roles of GOLPH3 in the Physiopathology of Cancer

Sechi

Frappaolo

Karimpour-Ghahnavieh

et al. 2020

IJMS

View full text Add to dashboard Cite

Golgi phosphoprotein 3 (GOLPH3), a Phosphatidylinositol 4-Phosphate [PI(4)P] effector at the Golgi, is required for Golgi ribbon structure maintenance, vesicle trafficking and Golgi glycosylation. GOLPH3 has been validated as an oncoprotein through combining integrative genomics with clinopathological and functional analyses. It is frequently amplified in several solid tumor types including melanoma, lung cancer, breast cancer, glioma, and colorectal cancer. Overexpression of GOLPH3 correlates with poor prognosis in multiple tumor types including 52% of breast cancers and 41% to 53% of glioblastoma. Roles of GOLPH3 in tumorigenesis may correlate with several cellular activities including: (i) regulating Golgi-to-plasma membrane trafficking and contributing to malignant secretory phenotypes; (ii) controlling the internalization and recycling of key signaling molecules or increasing the glycosylation of cancer relevant glycoproteins; and (iii) influencing the DNA damage response and maintenance of genomic stability. Here we summarize current knowledge on the oncogenic pathways involving GOLPH3 in human cancer, GOLPH3 influence on tumor metabolism and surrounding stroma, and its possible role in tumor metastasis formation.

show abstract

Section: Golph3 Deregulation and Brain Tumorsmentioning

confidence: 94%

Section: Golph3 Deregulation and Brain Tumorsmentioning

confidence: 99%

Oncogenic Roles of GOLPH3 in the Physiopathology of Cancer

Sechi

Frappaolo

Karimpour-Ghahnavieh

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…They demonstrated that Angiopep-2modified cationic lipid polymer crosses the BBB. Gefitinib can inhibit EGFR signaling and block the autophosphorylation of critical tyrosine residues on EGFR whereas GOLPH3 siRNA downregulate GLOPH3 expression (Ye et al, 2019).…”

Section: Tumormentioning

confidence: 99%

Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs

2020

View full text Add to dashboard Cite

Central nervous system (CNS) disorders especially neurodegenerative disorders are the major challenge for public health and demand the great attention of researchers to protect people against them. In past few decades, different treatment strategies have been adopted, but their therapeutic efficacy are not enough and have only shown partial mitigation of symptoms. Blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BSCFB) guard the CNS from harmful substances and pose as the major challenges in delivering drugs into CNS for treatment of CNS complications such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), stroke, epilepsy, brain tumors, multiple sclerosis (MS), and encephalitis, etc. Nanotechnology has come out as an exciting and promising new platform of treating neurological disorders and has shown great potential to overcome problems related to the conventional treatment approaches. Molecules can be nanoengineered to carry out multiple specific functions such as to cross the BBB, target specific cell or signaling pathway, respond to endogenous stimuli, and act as a vehicle for gene delivery, support nerve regeneration and cell survival. In present review, the role of nanocarrier systems such as liposomes, micelles, solid lipid nanoparticles (SLNPs), dendrimers, and nanoemulsions for delivery of various neurotherapeutic agents has been discussed, besides this, their mechanism of action, and nanoformulation of different neuroprotective agents like curcumin, edaravone, nerve growth factors in CNS disorders like Alzheimer's, Parkinsonism, epilepsy, stroke, and brain tumors has been reviewed.

show abstract

“…43) Therefore, the ApoE protein or ApoE-derived peptide modification approach targeting LDLR was developed. [44][45][46] LDLR family-targeting peptides, such as Angiopep-2 [47][48][49] or Peptide-22 50,51) were also developed. Chen et al evaluated the BBB-targeting ability of liposomes modified with various BBB-targeting (Angiopep-2, T7, Peptide-22) and gliomatargeting (c(RGDfK), D-SP5, peptide-1) ligands.…”

Section: Formulationmentioning

confidence: 99%

“…105) However, Tamaru et al developed plasmid DNA-encapsulated liposomal nanoparticles with a neutral charge and they succeeded in efficient transfection in the SVZ. 46) Recently, external stimuli have been used to deliver transfected genes via ICV administration. Bugeon et al genetically manipulated NSCs and neuronal cells in the SVZ by ICV injection of mRNA followed by electroporation.…”

Section: Intraventricular Administrationmentioning

confidence: 99%

Recent Strategies for Targeted Brain Drug Delivery

2020

View full text Add to dashboard Cite

Because the brain is the most important human organ, many brain disorders can cause severe symptoms. For example, glioma, one type of brain tumor, is progressive and lethal, while neurodegenerative diseases cause severe disability. Nevertheless, medical treatment for brain diseases remains unsatisfactory, and therefore innovative therapies are desired. However, the development of therapies to treat some cerebral diseases is difficult because the blood-brain barrier (BBB) or blood-brain tumor barrier prevents drugs from entering the brain. Hence, drug delivery system (DDS) strategies are required to deliver therapeutic agents to the brain. Recently, brain-targeted DDS have been developed, which increases the quality of therapy for cerebral disorders. This review gives an overview of recent brain-targeting DDS strategies. First, it describes strategies to cross the BBB. This includes BBB-crossing ligand modification or temporal BBB permeabilization. Strategies to avoid the BBB using local administration are also summarized. Intrabrain drug distribution is a crucial factor that directly determines the therapeutic effect, and thus it is important to evaluate drug distribution using optimal methods. We introduce some methods for evaluating drug distribution in the brain. Finally, applications of brain-targeted DDS for the treatment of brain tumors, Alzheimer's disease, Parkinson's disease, and stroke are explained.

show abstract

Co-delivery of GOLPH3 siRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma

Cited by 32 publications

References 50 publications

Oncogenic Roles of GOLPH3 in the Physiopathology of Cancer

Oncogenic Roles of GOLPH3 in the Physiopathology of Cancer

Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs

Recent Strategies for Targeted Brain Drug Delivery

Contact Info

Product

Resources

About